Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Sohn, Hyung Rae ^a   Min, Bo Young ^a   Song, Joon Chang ^a   Seong, Mun Hyuk ^a   Lee, Sang Soo ^a   Jang, Eun Sun ^a   Shin, Cheol Min ^a   Park, Young Soo ^a,b   Hwang, Jin Hyeok ^a,b   Jeong, Sook Hyang ^a,b   Kim, Nayoung ^a,b   Lee, Dong Ho ^a,b   Kim, Jin Wook ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; Discontinuation; Nucleos(t)ide analog; Relapse; Sustained response

Indexed keywords

CLEVUDINE; ENTECAVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; VIRUS DNA; ANTIVIRUS AGENT; GUANINE; URACIL ARABINOSIDE;

ADULT; AGED; COMORBIDITY; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RECURRENCE RISK; REMISSION; RETREATMENT; RETROSPECTIVE STUDY; REVIEW; SEROCONVERSION; SOUTH KOREA; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS REACTIVATION; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; BLOOD; GENOTYPE; HEPATITIS B, CHRONIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENT DISEASE; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84906821887     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-439     Document Type: Review

References (30)

1. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004, 351:1521-1531. 10.1056/NEJMoa033364, 15470215.
2. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936-962. 10.1016/j.cgh.2006.05.016, 16844425.
3. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, Okita K, Hayashi N, Okanoue T, Iino S, Tanikawa K. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res 2005, 32:173-184. 10.1016/j.hepres.2005.02.006, 16024289.
4. Europena Association for the Study of the liver EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185. Europena Association for the Study of the liver.
5. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662. 10.1002/hep.23190, 19714720.
6. Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010, 17:16-22. 10.1111/j.1365-2893.2009.01146.x, 19622117.
7. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008, 135:459-467. 10.1053/j.gastro.2008.05.031, 18585385.
8. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S,. Peginterferon alfa-2a in H-nCHBSG Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009, 136:2169-2179. e2161-2164, 10.1053/j.gastro.2009.03.006, 19303414, Peginterferon alfa-2a in H-nCHBSG.
9. Kobayashi M, Suzuki F, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Yatsuji H, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Iwasaki S, Miyakawa Y, Kumada H. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine. J Med Virol 2007, 79:1472-1477. 10.1002/jmv.20994, 17705186.
10. Europena Associatiion for the Study of the liver EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242. Europena Associatiion for the Study of the liver.
11. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Internat 2008, 2:263-283.
12. Yeh CT, Hsu CW, Chen YC, Liaw YF. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J Clin Virol 2009, 45:114-118. 10.1016/j.jcv.2009.04.006, 19451024.
13. Wang L, Liu F, Liu YD, Li XY, Wang JB, Zhang ZH, Wang YZ. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J Viral Hepat 2010, 17:298-304. 10.1111/j.1365-2893.2009.01178.x, 19758278.
14. Kuo YH, Chen CH, Wang JH, Hung CH, Tseng PL, Lu SN, Changchien CS, Lee CM. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol 2010, 45:75-81. 10.3109/00365520903394550, 20030580.
15. Lee HW, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Park JY, Kim do Y, Ahn SH, Paik YH, Lee CK, Lee KS, Chon CY, Han KH. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010, 51:415-421. 10.1002/hep.23323, 19902424.
16. Choi J, Kim JW, Seo JW, Chung CK, Kim KH, Kim JH, Kim JH, Chie EK, Cho HJ, Goo JM, Lee HJ, Wee WR, Nam SM, Lim MS, Kim YA, Yang SH, Jo EM, Hwang MA, Kim WS, Lee EH, Choi SH. Implementation of Consolidated HIS: Improving Quality and Efficiency of Healthcare. Healthc Inform Res 2010, 16:299-304. 10.4258/hir.2010.16.4.299, 3092134, 21818449.
17. The Korean Association for the Study of the L KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol 2012, 18:109-162. 3415874, 22893865, The Korean Association for the Study of the L.
18. Fung J, Lai CL, Tanaka Y, Mizokami M, Yuen J, Yuen MF, Wong DK. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 2009, 104:1940-1946. quiz 1947, 10.1038/ajg.2009.200, 19455108.
19. Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, Han KH, Chao YC, Lee SD, Harris M, Yang J, Colonno R, Brett-Smith H. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007, 133:1437-1444. 10.1053/j.gastro.2007.08.025, 17983800.
20. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010, 139:491-498. 10.1053/j.gastro.2010.03.059, 20381492.
21. Huang YH, Wu JC, Chang TT, Sheen IJ, Lee PC, Huo TI, Su CW, Wang YJ, Chang FY, Lee SD. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. J Viral Hepat 2003, 10:277-284. 10.1046/j.1365-2893.2003.00428.x, 12823594.
22. Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, Han S, Kaymakoglu S, Tamez R, Yang J, Tenney D, Brett-Smith H. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009, 50:289-295.
23. Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004, 11:432-438. 10.1111/j.1365-2893.2004.00556.x, 15357648.
24. Liu F, Wang L, Li XY, Liu YD, Wang JB, Zhang ZH, Wang YZ. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2011, 26:456-460. 10.1111/j.1440-1746.2010.06492.x, 21332542.
25. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Internat 2012, 6:531-561.
26. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006, 354:1001-1010. 10.1056/NEJMoa051285, 16525137.
27. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-1020. 10.1056/NEJMoa051287, 16525138.
28. Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, Han BH, Han JY, Byun KS, Cho M, Lee HJ, Kim TH, Cho SH, Park JW, Um SH, Hwang SG, Kim YS, Lee YJ, Chon CY, Kim BI, Lee YS, Yang JM, Kim HC, Hwang JS, Choi SK, Kweon YO, Jeong SH, Lee MS, Choi JY, Kim DG, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007, 45:1172-1178. 10.1002/hep.21629, 17464992.
29. Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, Lee KS, Han BH, Chon CY, Han JY, Ryu SH, Kim HC, Byun KS, Hwang SG, Kim BI, Cho M, Yoo K, Lee HJ, Hwang JS, Lee YS, Choi SK, Lee YJ, Yang JM, Park JW, Lee MS, Kim DG, Chung YH, Cho SH, Choi JY, Kweon YO, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007, 46:1041-1048. 10.1002/hep.21800, 17647293.
30. Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, Liaw YF. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013, 58:1888-1896. 10.1002/hep.26549, 23744454.